Clinical Trial Update: A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GLPG3970 as an oral treatment for 6 weeks in adults with ulcerative colitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• GLPG3970 (GLPG3970)

Snippet

Sponsor: Galapagos NV | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED | Results posted: 2023-01-27